Formulation and evaluation of Etodolac and Triamcinolone Acetonide loaded nano lipid carrier gels for the therapeutic management of Osteoarthritis Pain through topical administration: A Comparative Study

Souvik Chakraborty; N. Vishal Gupta; Vikas Jain; Balamuralidhara V

doi:10.22159/ijap.2024v16i5.51326

Authors

Souvik Chakraborty Department of Pharmaceutics, JSS College of Pharmacy
N. Vishal Gupta Department of Pharmaceutics, JSS College of Pharmacy
Vikas Jain Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Mysore- 570015, Karnataka, India
Balamuralidhara V Department of Pharmaceutics, JSS College of Pharmacy

DOI:

https://doi.org/10.22159/ijap.2024v16i5.51326

Keywords:

Etodolac, Triamcinolone Acetonide, Osteoarthritis, Nano-lipid carriers, Gels

Abstract

Objective: The present study aims to prepare carbopol-based hydrogels loaded with EDT, and TCA incorporated nanolipid carriers (EDTg and TCAg) to compare the efficacy and potency of both drugs for OA pain management.

Method: EDT-NLCs and TCA-NLCs were prepared with the help of the solvent evaporation method after screening the lipids, and the NLCs were optimized. The optimized NLC formulations EDT-NLC and TCA-NLCs were examined for particle size (PS), PDI, zeta potential (ZP), DSC (PXRD), TEM and in vitro release. The prepared NLCs-loaded hydrogels have been evaluated with in-vitro drug release, ex-vivo skin permeation, and in vivo pharmacokinetic and pharmacodynamic parameters.

Results: DSC and PXRD graphs showed a decrease in melting point and the amorphous form of the optimized NLC formulation. Different evaluation tests revealed that the EDT-NLCs and TCA-NLCs had particle size (PS) of 161 ± 0.0021 nm and 167.4 ± 0.0010 nm, PDI of 0.148 ± 0.023 and 0.130 ± 0.01, and ZP of -14 mV and -15 mV respectively, indicating their distinct nature. In vitro drug release study, ETDg showed 89.84 ± 1.71 % release, while TCAg released 94.75 ± 1.79 % after 24 hours of application. ETDg permeated 86.5 ± 1.68 % of EDT-NLCs through the dorsal skin, compared to TCA-NLCs 76.5 ± 1.13 % in an ex vivo skin permeation investigation. A pharmacokinetic study identified 76.3 ± 1.98 % of EDT-NLCs and 63.25 ± 2.003 of TCA-NLCs in drug plasma. Pharmacodynamic characteristics like X-ray analysis, IHC, and histopathology indicated that EDTg and TCAg managed OA pain. All evaluation tests carried out in this research showed that formulated hydrogels could manage OA.

Downloads

Download data is not yet available.

Author Biographies

N. Vishal Gupta, Department of Pharmaceutics, JSS College of Pharmacy

Professor

Department of Pharmaceutics,

JSS College of Pharmacy,

Sri Shivarathreeshwara Nagara,

JSS Academy of Higher Education and Research, Mysuru – 570015,

Karnataka, India.

Balamuralidhara V, Department of Pharmaceutics, JSS College of Pharmacy

Associate Professor and Head

Department of Pharmaceutics,

JSS College of Pharmacy,

Sri Shivarathreeshwara Nagara,

JSS Academy of Higher Education and Research, Mysuru – 570015,

Karnataka, India.

References

Anandacoomarasamy A, March L. Current evidence for osteoarthritis treatments. Ther Adv Musculoskelet Dis 2010;2:17–28.

Boer CG, Hatzikotoulas K, Southam L, Stefánsdóttir L, Zhang Y, et al. Deciphering osteoarthritis genetics across 826,690 individuals from 9 populations. Cell 2021;184:4784-4818.

Wieland HA, Michaelis M, Kirschbaum BJ, Rudolphi KA. Osteoarthritis—an untreatable disease?. Nature reviews Drug discovery 2005;4:331-344.

Bannuru RR, Osani MC, Vaysbrot EE, Arden NK, Bennell K, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage 2019;27:1578–1589.

Kolasinski SL, Neogi T, Hochberg MC, Oatis C, Guyatt G, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care Res (Hoboken) 2020;72:149–162.

Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 2012;64: 465–474.

Jordan, KM. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003;62:1145–1155.

McAlindon TE, Bannuru RR, Sullivan MC, Arden NK, Berenbaum F, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage 2014;22:363–388.

Da Costa BR, Pereira TV, Saadat P, Rudnicki M, Iskander SM, et al. Effectiveness and safety of non-steroidal anti-inflammatory drugs and opioid treatment for knee and hip osteoarthritis: network meta-analysis. Bmj 2021;12:375.

Scarpignato C, Lanas A, Blandizzi C, Lems WF, Hermann M, et al. Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis – an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks. BMC Med 2015;13: 55.

Zeng C, Wei J, Persson MSM, Sarmanova A, Doherty M, et al. Relative efficacy and safety of topical non-steroidal anti-inflammatory drugs for osteoarthritis: a systematic review and network meta-analysis of randomized controlled trials and observational studies. Br J Sports Med 2018;52:642–650.

Hochberg MC, Altman RD, Brandt KD, Clark BM, Dieppe PA, et al. Guidelines for the medical management of osteoarthritis. Arthritis Rheum 1995;38:1541–1546.

Zhang Y, Cun D, Kong X, Fang L. Design and evaluation of a novel transdermal patch containing diclofenac and teriflunomide for rheumatoid arthritis therapy. Asian J Pharm Sci 2014;9:251–259.

von Heideken J, Chowdhry S, Borg J, James K, Iversen MD. Reporting of harm in randomized controlled trials of therapeutic exercise for knee osteoarthritis: a systematic review. Physical therapy 2021;101:161.

Abdellatif AAH, El-Telbany DFA, Zayed G, Al-Sawahli M.M. Hydrogel Containing PEG-Coated Fluconazole Nanoparticles with Enhanced Solubility and Antifungal Activity. J Pharm Innov 2019;14:112–122.

Karadzovska D, Brooks JD, Riviere JE. Modeling the effect of experimental variables on the in vitro permeation of six model compounds across porcine skin. Int J Pharm 2013;443: 58–67.

Kurakula M, Ahmed OAA, Fahmy UA, Ahmed TA. Solid lipid nanoparticles for transdermal delivery of avanafil: optimization, formulation, in-vitro and ex-vivo studies. J Liposome Res 2016;26:288–296.

Schnitzer TJ, Ballard IM, Constantine G, McDonald P. Double-blind, placebo-controlled comparison of the safety and efficacy of orally administered etodolac and nabumetone in patients with active osteoarthritis of the knee. Clin Ther 1995:17;602–612.

van Middelkoop M, Arden NK, Atchia I, Birrell F, Chao J, et al. The OA Trial Bank: meta-analysis of individual patient data from knee and hip osteoarthritis trials show that patients with severe pain exhibit greater benefit from intra-articular glucocorticoids. Osteoarthritis Cartilage 2016;24:1143–1152.

Xing D, Yang Y, Ma X, Ma J, Ma B, Chen Y. Dose intraarticular steroid injection increase the rate of infection in subsequent arthroplasty: grading the evidence through a meta-analysis. J Orthop Surg Res 2014;9:107.

Mohammadi M, Pezeshki A, Mesgari Abbasi M, Ghanbarzadeh B, Hamishehkar H. Vitamin D3-Loaded Nanostructured Lipid Carriers as a Potential Approach for Fortifying Food Beverages; In vitro and In vivo Evaluation. Adv Pharm Bull 2017;7:61–71.

Radha GV, Sastri KT, Prathyusha P, Bhanu P, Rajkumar J. Formulation and evaluation of aceclofenac proniosome loaded orabase for management of dental pain. Int J Appl Pharm. 2018;10:204-210.

Iqbal B, Ali J, Baboota S. Silymarin loaded nanostructured lipid carrier: From design and dermatokinetic study to mechanistic analysis of epidermal drug deposition enhancement. J Mol Liq 2018;255:513–529.

Patel DK, Kesharwani R, Kumar V. Etodolac loaded solid lipid nanoparticle based topical gel for enhanced skin delivery. Biocatal Agric Biotechnol 2020;29:101810.

Kawadkar J, Pathak A, Kishore R, Chauhan MK. Formulation, characterization and in vitro–in vivo evaluation of flurbiprofen-loaded nanostructured lipid carriers for transdermal delivery. Drug Dev Ind Pharm 2013;39:569–578.

Chand P, Kumar H, Badduri N, Gupta NV, Bettada VG, et al. Design and evaluation of cabazitaxel loaded NLCs against breast cancer cell lines. Colloids Surf B Biointerfaces 2021;199:111535.

Mohammadi-Samani S, Zojaji S, Entezar-Almahdi E. Piroxicam loaded solid lipid nanoparticles for topical delivery: Preparation, characterization and in vitro permeation

assessment. J Drug Deliv Sci Technol 2018;47:427-33

Jain K, Sood S, Gowthamarajan K. Optimization of artemether-loaded NLC for intranasal delivery using central composite design. Drug Deliv 2015;22:940–954.

Hu FQ, Jiang SP, Du YZ, Yuan H, Ye YQ, Zeng S. Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system. Colloids Surf B Biointerfaces 2005;45:167–173.

Wamorkar V, Varma MM, Manjunath SY. Formulation and evaluation of stomach specific in-situ gel of metoclopramide using natural, bio-degradable polymers. International Journal of Research in Pharmaceutical and Biomedical Sciences 2011;2:193–201.

Zhuang CY, Li N, Wang M, Zhang XN, Pan WS, et al. Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability. Int J Pharm 2010;394:179–185.

Luo Q, Zhao J, Zhang X, Pan W. Nanostructured lipid carrier (NLC) coated with Chitosan Oligosaccharides and its potential use in ocular drug delivery system. Int J Pharm 2011;403:185-191.

Shah NV, Seth AK, Balaraman R, Aundhia CJ, Maheshwari RA, Parmar GR. Nanostructured lipid carriers for oral bioavailability enhancement of raloxifene: Design and in vivo study. J Adv Res 2016;7:423–434.

He Y, Majid K, Maqbool M, Hussain T, Yousaf AM, et al. Formulation and characterization of lornoxicam-loaded cellulosic-microsponge gel for possible applications in arthritis. Saudi Pharmaceutical Journal. 2020;28:994-1003.

Souto EB, Wissing SA, Barbosa CM, Müller RH. Evaluation of the physical stability of SLN and NLC before and after incorporation into hydrogel formulations. European J Pharm and Biopharm 2004;58:83–90.

Bove SE, Calcaterra SL, Brooker RM, Huber CM, Guzman RE, Juneau PL. Weight bearing as a measure of disease progression and efficacy of anti-inflammatory compounds in a model of monosodium iodoacetate-induced osteoarthritis. Osteoarthritis Cartilage 2003;11:821–830.

Patel KN, Patel HK, Patel VA. Formulation and characterization of drug in adhesive transdermal patches of diclofenac acid. Int J Pharm Pharm Sci 2012;4;296–299.

Vashisth I, Ahad A, Aqil M, Agarwal SP. Investigating the potential of essential oils as penetration enhancer for transdermal losartan delivery: Effectiveness and mechanism of action. Asian J Pharm Sci 2014;9:260–267.

Danafar H, Hamidi M. Simple and Sensitive High-Performance Liquid Chromatography (HPLC) Method with UV Detection for Mycophenolic Acid Assay in Human Plasma. Application to a Bioequivalence Study. Adv Pharm Bull 2015;5:563–568.

Liu SC, Lee HP, Hung CY, Tsai CH, Li TM, Tang CH. Berberine attenuates CCN2-induced IL-1β expression and prevents cartilage degradation in a rat model of osteoarthritis. Toxicol Appl Pharmacol 2015;289: 20–29.

Bhalekar MR. Solid lipid nanoparticles incorporated transdermal patch for improving the permeation of Piroxicam. . Asian J Pharm 2016;10.

Ah YC, Choi JK, Choi YK, Ki HM, Bae JH. A novel transdermal patch incorporating meloxicam: In vitro and in vivo characterization. Int J Pharm 2010;385:12–19.

Sun L, Cun D, Yuan BO, Cui H, Xi H, et al. Formulation and in vitro/in vivo correlation of a drug‐in‐adhesive transdermal patch containing azasetron. J Pharm Sci 2012;101:4540–4548.

Sastri KT, Gupta NV, Kannan A, Balamuralidhara V, Ramkishan A. Potential nanocarrier-mediated miRNA-based therapy approaches for multiple sclerosis. Drug Discovery Today. 2022;27:103357.

Juneja SC, Ventura M, Jay GD, Veillette C. A less invasive approach of medial meniscectomy in rat: a model to target early or less severe human osteoarthritis. J Arthritis 2016;5;1–17.

Mishra N, Mishra M, Padh H. Formulation development and optimization of efavirenz loaded SLNs and NLCs using plackett-burman design and its statistical elucidation. Int. J. Pharm. Res. Health Sci, 6, 2379-2388. Int J Pharm R H Sci 2018;6:2379–2388.

Gönüllü Ü, Üner M, Yener G, Karaman EF, Aydoğmuş Z. Formulation and characterization of solid lipid nanoparticles, nanostructured lipid carriers and nanoemulsion of lornoxicam for transdermal delivery. Acta Pharmaceutica 2015;65;1–13.

Li X, Nie S, Kong J, Li N, Ju C, Pan W. A controlled-release ocular delivery system for ibuprofen based on nanostructured lipid carriers. Int J Pharm 2008;363:177–182.

Unger WWJ, van Beelen AJ, Bruijns SC, Joshi M, Fehres CM, et al. Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells. J Controlled Release 2012;160:88–95.

Gaba B, Fazil M, Khan S, Ali A, Baboota S, Ali J. Nanostructured lipid carrier system for topical delivery of terbinafine hydrochloride. Bulletin of Faculty of Pharmacy, Cairo University 2015;53:147–159.

Abdelbary G, Haider M. In vitro characterization and growth inhibition effect of nanostructured lipid carriers for controlled delivery of methotrexate. Pharm Dev Technol 2013;18:1159–1168.